Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...

Humira has been off-patent for more than a ... One of the newer products has already got off to a good start – psoriasis drug Skyrizi pulled in a respectable $311 million after FDA approval ...

Biologics, which appear to have a safer risk-to-benefit ratio compared to cyclosporine, have more or less supplanted this drug for psoriasis in most patients. Humira (adalimumab) is a commonly ...

Humira’s success is down to its incredible versatility – an anti-TNF drug, it is approved in a range of inflammatory diseases, including rheumatoid arthritis, plaque psoriasis and Crohn’s ...

Q. Is there any cure for psoriasis? A. There’s no cure for psoriasis yet, but there are many ways to get relief from the symptoms of this troublesome disease. Psoriasis is one of the most ...

Humira has been a blockbuster worldwide for nearly two decades. The biologic has multiple indications, including rheumatoid arthritis, Crohn’s disease and psoriasis. The Foundation asserts that ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

Psoriasis is a chronic skin disorder characterized ... Three other biologics — adalimumab (Humira; Abbott), etanercept (Enbrel; Amgen/Wyeth/Takeda) and infliximab (Remicade; Centocor Ortho ...

With approvals in rheumatoid arthritis, psoriasis, and Crohn's disease, Humira holds a wide range of indications, but biosimilar versions of the drug led to price erosion beginning in 2023 and ...

Medscape Medical News, December 03, 2024 Psoriasis: Adalimumab Biosimilars Comparable With Originator Biosimilars show comparable safety with Humira among new users with psoriasis in a ...

UnitedHealth to Remove AbbVie's Humira From Some US Drug Reimbursement ... differences in the risk for PsA among patients with psoriasis treated with interleukin (IL)-23 inhibitors and those ...